BML-111 (Standard)

BML-111 (Standard) is the analytical standard of BML-111 (HY-100450) . This product is intended for research and analytical applications. BML-111, a lipoxin A4 analog, is a lipoxin A4 receptor agonist. BML-111 represses the activity of angiotensin converting enzyme (ACE) and increases the activity of angiotensinconverting enzyme 2 (ACE2) . BML-111 has antiangiogenic, antitumor and anti-inflammatory properties[1][2].

Product Specifications

CAS Number

[78606-80-1]

Target

Angiotensin-converting Enzyme (ACE) ; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Smiles

O=C(OC)CCC[C@H](O)[C@H](O)CO

Molecular Formula

C8H16O5

Molecular Weight

192.21

References & Citations

[1]Ying Chen, et al. Lipoxin A4 and Its Analogue Suppress the Tumor Growth of Transplanted H22 in Mice: The Role of Antiangiogenesis. Mol Cancer Ther. 2010 Aug;9 (8) :2164-74.|[2]Qiong-Feng Chen, et al. BML-111, a Lipoxin Receptor Agonist, Protects Against Acute Injury via Regulating the Renin Angiotensin-Aldosterone System. Prostaglandins Other Lipid Mediat. 2019 Feb;140:9-17.|[3]T H Lee, et al. Inhibition of Leukotriene B4-induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships. Biochem Biophys Res Commun. 1991 Nov 14;180 (3) :1416-21.